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Abstract
Objective The aim of this pilot study was to test and
demonstrate the feasibility of simultaneous positron emis-
sion tomography (PET) and magnetic resonance imaging
(MRI) of the head and upper neck area using a new hybrid
PET/MRI system.
Methods Eight patients with malignant head and neck
tumours were included in the pilot study. Directly after
routine PET/CT imaging with a whole-body system using the
glucose derivative 2-[18F]fluoro-2deoxy-D-glucose (FDG) as
a radiotracer additional measurements were performed with a
prototype PET/MRI system for simultaneous PET and MR
imaging. Physiological radiotracer uptake within regular
anatomical structures as well as tumour uptake were evaluated
visually and semiquantitatively (metabolic ratios) in relation
to cerebellar uptake on the PET/MRI and PET/CT systems.
Results The MR datasets showed excellent image quality
without any recognisable artefacts caused by the inserted PET
system. PET images obtained with the PET/MRI system
exhibited better detailed resolution and greater image contrast
in comparison to those from the PET/CTsystem. An excellent
agreement between metabolic ratios obtained with both PET
systems was found: R=0.99 for structures with physiological
tracer uptake, R=0.96 for tumours.
Conclusion Simultaneous PET/MRI of the head and upper
neck area is feasible with the new hybrid PET/MRI prototype.
Keywords PET/MRI . Hybrid imaging . Head and neck
tumours . Oncology
Introduction
Head and neck cancer has an incidence of approximately
10–20 cases per 100,000 persons in Germany with a 3- to
4-times higher risk for male patients [1]. Most of the
tumours are squamous cell carcinomas. Selection of an
optimal treatment strategy requires the accurate staging of
the tumour extent with respect to primary tumour site and
size, infiltration of adjacent soft tissue and osseous
structures as well as regional lymph node involvement.
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Usually morphological imaging is performed by
contrast-enhanced computed tomography (CT) or magnetic
resonance imaging (MRI). MRI provides several advantages
over CT such as increased soft-tissue contrast and reduced
artefacts close to the skull base and near metallic tooth
implants. As many of the head and neck tumours are sensitive
to radiotherapy, the higher soft-tissue contrast of MRI is
especially useful for identifying an accurate target volume and
critical organs. Salivary glands should be spared from
irradiation to prevent postradiotherapy xerostomia [2].
There is increasing evidence that additional metabolic
imaging with the glucose derivative [18F]fluoro-deoxy-glucose
(FDG), using either dedicated positron emission tomography
(PET) devices or combined PET/CT systems, can significantly
enhance staging accuracy [3, 4]. FDG-PET may identify
tumour infiltration of lymph nodes, in which neither CT nor
MRI show characteristic pathological imaging findings.
Moreover, it can help to distinguish residual or recurrent
disease and post-therapeutic changes. Therefore, FDG-PET
can complement MRI and CT imaging [5, 6].
While combined PET/CT devices are now firmly
established in routine oncological imaging, the PET/MRI
technique has only been introduced for initial clinical
evaluation. Unlike current PET/CT systems, several of the
PET/MRI designs allow for simultaneous instead the
sequential data acquisition known from PET/CT. This new
generation of hybrid systems combines the excellent
anatomical resolution and high soft-tissue contrast of MRI
with the highly sensitive evaluation of metabolism and
molecular processes achieved with PET. First prototypes of
hybrid PET/MRI scanners based on avalanche photodiodes
instead of photomultiplier tubes were developed for small
animal imaging [7]. The first hybrid PET/MRI systems
using the same technology for clinical applications have
recently been installed [8]. These prototypes consist of a
compact PET system (Siemens BrainPET), which fits into a
conventional high-field MRI. The system used for this
study combines the PET system with a slightly modified
clinical 3.0 T whole body MRI (Siemens Tim Trio).
The aim of this pilot study was to test the feasibility of
simultaneous PET/MR imaging of the head and upper neck
area in 8 patients with malignant head and neck tumours
and to evaluate PET image quality and the quantitation
accuracy of the PET/MRI system in comparison to PET/CT.
Materials and methods
Subjects and study protocol
Eight patients with head and neck cancer (7 male, 1 female;
age: 42–82 years, median age: 65.5 years) were included in
the study between 11/2008 and 11/2009. Patient details are
listed in Table 1. All patients first underwent clinically
indicated whole-body FDG-PET/CT imaging for staging
and immediately afterwards additional PET/MRI of the
head and upper neck region without additional radiotracer
administration. The study was approved by the local Ethics
committee. All patients gave their written informed consent to
the PET/CT and PET/MRI examinations as well as to the
scientific evaluation of the data.
PET/CT
Patients fasted overnight (for at least 6 h) before intrave-
nous injection of FDG (350–399 MBq, approx. 4 MBq per
kg body weight). All patients had blood glucose levels
within the normal range. The patients underwent a split
PET/CT protocol beginning with whole-body imaging from
the upper thorax to the mid-thigh level followed by separate
head and neck imaging according to standard clinical
protocols. PET/CT data acquisition (Hi-Rez Biograph 16
with a 3D-only PET component, Siemens Healthcare,
Knoxville, TN, USA) always started with a contrast-
enhanced CT after administration of 100–120 ml Ultravist
370 (Bayer-Schering Pharma AG, Berlin, Germany) for the
body imaging and bi-phasic bolus injection of 2×40 ml of
the same contrast agent for the head and neck imaging (first
bolus 2–3 min prior to the scan, second bolus 30 s prior to
the scan, 2 ml/sec injection rate). CT-scan parameters for
the head and neck imaging were as follows: 140 kVp
(kilovoltage peak), slice thickness 4 mm, no interslice gap,
field-of-view 323 mm, reconstruction matrix size 512×512,
slice resolution 0.63×0.63 mm, tube current 266 mAs. CT
was followed by the PET data acquisition; PET started
60 min after radiotracer injection with 3 min per bed for the
body imaging and 4 min for the head and neck imaging.
PET data were subsequently reconstructed into transaxial
slices (matrix size 256×256, voxel size 1.78 mm,
corresponding to a transaxial field of view (FOV) of
45.5×45.5 cm) using the manufacturer-provided standard
software (Fourier rebinning, 2D ordered-subset expectation
maximisation (OSEM) algorithm with 8 iterations, 16
subsets). The CT data were used for attenuation correction.
Average transverse and axial spatial resolutions (full width
at half maximum) of the Hi-Rez Biograph are 4.61 (5.10)
mm and 5.34 (5.91) mm, respectively, at 1 and 10 cm off
axis according to NEMA standards [9].
PET/MRI
System
All PET/MRI examinations were performed with a hybrid
PET/MRI system capable of simultaneous PET/MRI of the
head and upper neck region. The system consists of an
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MRI-compatible PET inserted into a slightly modified 3.0
Tesla whole-body MRI (BrainPET and Magnetom Tim
Trio, Siemens Healthcare, Erlangen, Germany). The technical
specifications of the PET insert have been described previously
[8]. In short, the PET detector technology relies on lutetium
oxyorthosilicate (LSO) scintillation crystals in combination
with MR-compatible avalanche photodiodes instead of
photomultiplier tubes. The PET system has a craniocaudal
field of view (FOV) of 19.1 cm and a transverse FOV of
32.0 cm. Spatial resolution is 2.5 mm (full width at half
maximum) in the centre and 4.5 mm at 10 cm off axis. All
image data were acquired in “list mode”, where the individual
coincidence events are stored on hard disk with the exact
detector location and timing information for retrospective
data histogramming and reconstruction.
The modifications of the MRI machine comprise the
deactivation of the built-in body transmitter and alterations
of the MRI patient handling system to allow for precise
mounting of the head-coil within the PET system, thereby
matching the two FOVs. It is only possible to scan one bed
position (head and upper neck area) since the restricted
space within the PET insert precludes movement of the
patient’s body. A dedicated birdcage transmit-receive head-coil
was used for spin excitation, which was combined with an
inner 8-channel receive-only head-coil. The gradient system
operates with a maximum gradient strength of 40 mT/m and a
slew rate of 200 T/m/sec in all three axes.
Data acquisition
PET and MRI data acquisition were simultaneously started
30 to 60 min after PET/CT imaging. PET data were
acquired for 25 min and subsequently rebinned and
reconstructed using a 3D OSEM algorithm [10] (matrix
size 256×256×153, voxel size 1.25 mm in all directions,
corresponding to the aforementioned transaxial FOV of
32.0 cm and craniocaudal coverage of 19.1 cm). PET
imaging time was longer than for PET/CT imaging since
with PET/MRI both modalities acquire data simultaneously
and total scanning time was governed by MR imaging, so
that a longer PET acquisition time came without a time loss.
Own previous data (not shown) have indicated that this
does not affect the quantification as used within this study.
The attenuation maps were computed from 3D MRI
datasets applying an algorithm combining pattern recognition
and atlas registration [11].
The MRI examination protocol included Gradient-Echo
(GRE) localisers, a transverse T1-weighted 3D-encoded
GRE sequence for attenuation correction (repetition time
(TR)/echo time (TE) 4.6 ms/2.46 ms, excitation angle 10°,
matrix size 256×256×160, cubic voxels with a size of
1.25 mm in all directions, bandwidth 590 Hz/px, parallel
imaging GRAPPA factor 2), a transverse 2D-encoded Fluid
Attenuated Inversion Recovery (FLAIR) sequence (TR/TE
9000/87, echo train length 16, inversion time (TI) 2.5 s,
matrix size 256×232, in-plane resolution 0.78 mm×
0.78 mm, slice thickness 3 mm, bandwidth 200 Hz/px), a
T2-weighted 2D-encoded Fast Spin-Echo (FSE) sequence
in transverse, sagittal and coronal orientations (TR/TE
5000/90, echo train length 17, matrix size 512×512, in-
plane resolution 0.39×0.29 mm², slice thickness 3 mm, pixel
bandwidth 190 Hz/px) as well as a sagittal 3D-encoded
Magnetisation Prepared Rapid Acquisition Gradient Echo
(MPRAGE) sequence (TR/TE 1900/2.4, TI 0.9 s, matrix size
512×512×338, resolution 0.49 mm×0.49 mm×0.9 mm,
bandwidth 190 Hz/px, parallel imaging GRAPPA factor 2).
Total acquisition time was approximately 30–40 min. In
compliance with Ethics committee regulations, no contrast
medium was injected during PET/MRI.
Data analysis
PET and MRI datasets from the simultaneous PET/MRI
sessions were transferred to a separate computer system for
subsequent data analysis. Image quality of the PET and MR
images obtained with the hybrid PET/MRI system was
Table 1 Patient characteristics
Patient Age Gender [m/f] Diagnosis Dose [MBq] Dose per kg body
weight [MBq/kg]
1 42 m squamous cell carcinoma, scalp 399 3.8
2 84 m nasopharyngeal carcinoma 391 4.4
3 66 m nasopharyngeal carcinoma 389 5.1
4 54 f nasopharyngeal carcinoma 386 8.0
5 73 m lymph node metastasis, squamous cell carcinoma, scalp 350 4.7
6 64 m lymph node metastasis, cup syndrome 352 5.4
7 68 m nasopharyngeal carcinoma 381 5.2
8 65 m nasopharyngeal carcinoma 367 4.1
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visually evaluated by two board-certified radiologists and
one board-certified nuclear medicine physician with regard
to the visualisation of anatomical structures and malignant
tumours and the presence of image artefacts. PET images
were compared with those from PET/CT imaging.
Subsequent semiquantitative image analysis was per-
formed with the VINCI software package (“Volume
Imaging in Neurological Research, Co-Registration and
ROIs included”, version 3). For ROI analysis, PET datasets
from PET/MRI and PET/CT were co-registered to the T1-
weighted 3D MPRAGE dataset with the VINCI software
tool “MMM Co-Registration”. Two-dimensional ROIs were
drawn on the PET/CT images over regular anatomical
structures of the head and neck region with known FDG
uptake (base of tongue, gingiva, adenoids of the nasophar-
ynx, palatine tonsils, parotid glands, sublingual gland and
turbinates) and over tumour manifestations. ROIs were
defined on the plane that contained the maximum tracer
uptake. Additionally, a large free-hand ROI was drawn over
the cerebellum on a slice dissecting the cerebellum at mid-
level. All ROIs were copied to the co-registered PET/MRI
datasets in order to avoid a bias due to different ROI
definitions for the PET/MRI and PET/CT datasets.
As absolute quantification of the PET datasets is not yet
possible with the prototype PET/MRI system, the radionu-
clide uptake of the above-defined anatomical structures and
tumour manifestations was quantified in relation to mean
cerebellar uptake, as previously described [12, 13]. The
terms mean and maximum metabolic ratios were defined as
the ratio of the mean and maximum uptake, respectively,
within the head and neck ROIs and the mean cerebellar
uptake. The average over all patients of the metabolic ratios
for each structure was then determined and termed the
average (mean or maximum) metabolic ratio. If the regular
anatomical structure was too close to tumour tissue, no ROI
analysis was performed on that structure to avoid spill-over
errors. For quantification of physiological uptake in regular
anatomical structures of the head and neck region only the
mean metabolic ratios were calculated; for tumour mani-
festations both the mean and maximum metabolic ratios
were derived, analogous to the previously described
evaluation scheme [12, 13].
Results
The MRI datasets acquired during simultaneous PET data
acquisition exhibited excellent image quality similar to a
conventional 3.0 Tesla Tim Trio system without any
recognisable additional artefacts or distortions caused by
the PET insert. The PET datasets showed slight streak
artefacts, which were most prominent in the sagittal and
coronal reformations (Fig. 1). These streak artefacts did not
lead to degradation of the tumour visualisation. Because of
the higher resolution of the PET component of the PET/MRI
system in comparison to the PET component of the PET/CT
system, small anatomical structures such as orbicular muscles
were better delineated and showed a better contrast to the
background. A typical example is given in Fig. 2. The axial
field of view of the PET insert typically reached caudally
only to the level II lymph node regions. The hypopharynx and
the larynx were outside of the FOV. In two patients, no
malignant tumour tissue was detected within the imaging
region of the PET insert: in patient 4 after radiotherapy, no
residual tumour tissue was found on either PET/MRI or PET/
CT imaging; whereas in patient 6 a metabolically active
lymph nodemetastasis was identified with the PET/CTsystem
in the level III region, which was outside of the FOV of the
PET/MRI system. An example of tracer uptake in lymph node
metastases in the upper neck region is provided in Fig. 3.
The average (mean) metabolic ratios for the regular
anatomical structures are provided in Table 2, additional
values taken from the literature are also given. Excellent
agreement between the averaged PET/MRI values and the
respective PET/CT values was found. The correlation
coefficient was R=0.99. Furthermore, the averaged meta-
bolic ratios showed good agreement with literature values.
In Fig. 4, the average values of the physiological uptake are
displayed together with the corresponding linear regression
line. The average tumour uptake in PET/MRI is signifi-
cantly higher compared with PET/CT; however, a certain
overlap exists. A scatter plot of individual values for the
mean and maximum metabolic ratios for the tumour
manifestations in the head and upper neck region is
presented in Fig. 5. For the mean metabolic ratios, the
correlation coefficient was R=0.92, and for the maximum
metabolic ratios the correlation coefficient was R=0.96.
The mean metabolic ratios of the tumours are close to the
line of identity, whereas the maximum values were slightly
higher for the PET/MRI system in comparison to PET/CT.
Discussion
In this pilot study involving 8 patients, it was shown that
simultaneous PET/MRI of head and neck cancer is feasible.
No notable degradation of MR image quality during
simultaneous PET data readout was observed. The spatial
resolution of the PET component of the PET/MRI system
was visibly better compared with that of conventional PET/
CT, mainly owing to the smaller diameter of the PET
detector ring and smaller scintillation crystal sizes; quanti-
fication accuracy of tumour uptake in relation to reference
tissue was comparable.
The PET insert offers a spatial resolution in the
reconstructed datasets of ~3 mm full width at half
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maximum (FWHM) compared with 5–6 mm FWHM for
the PET/CT system. This is most obvious in the delineation
of small anatomical structures such as intraorbital struc-
tures. Better spatial resolution may translate into more exact
delineation of metabolically active tumour tissue, a better
assessment of skull base infiltration and an improved
detectability of small lymph node metastases in head and
neck cancer.
The computed metabolic ratios of the regular anatomical
structures and the tumours are in excellent agreement with
the PET/CT data as well as the reported literature values
[12, 13]. The maximum metabolic ratios of the tumours
show a linear deviation from the identity line with higher
values in the PET/MRI datasets. This observation may be
attributed to the higher spatial resolution with smaller spill-over
and partial volume effects.
The PET datasets obtained with the PET/MRI prototype
system still exhibited slight streak artefacts, which, howev-
er, did not notably compromise the assessment of the
tumours evaluated. Several design characteristics of the
prototype PET/MRI system may contribute to these
artefacts. As an example, each PET detector system features
gaps between detector blocks; however, the gaps influence
the normalisation in small bore-diameter systems like in the
Fig. 1 FDG-PET/MRI of a 65-year-old patient with nasopharyngeal
carcinoma (white arrow). T1-weighted MR images in transaxial (top),
coronal (middle) and sagittal (bottom) directions are displayed on the
left, FDG-PET and MRI fusion images in the centre and PET images
on the right. In the sagittal and coronal reformations, slight streak
artefacts, caused by normalisation issues, are visible
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Fig. 3 FDG-PET/MRI (top row) and FDG-PET/CT (bottom row)
images of bilateral level II cervical lymph node metastases of a
squamous cell carcinoma of the scalp in a 73-year-old patient. MRI
and CT images, respectively, are displayed on the left, fusion images
in the centre, and PET images on the right
Fig. 2 Sagittal FDG-PET/MRI (top row) and FDG-PET/CT (bottom
row) images of a left supraorbital metastasis of a nasopharyngeal
carcinoma (arrow) in a 66-year-old patient. T2-weighted MRI and CT,
respectively, are displayed on the left, fusion images in the centre and
PET on the right. The data set from PET/MRI shows a better
delineation of intraorbicular muscles (arrow heads)
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BrainPET more than in whole-body systems. Additionally,
the send and receive coils of the MRI system reside inside
the PET detector ring which complicates attenuation and
scatter correction. As the prototype system is still under
constant development, the slight streak artefacts improved
significantly over the last 2 years and are expected to be
even less visible in the future when all effects are more
fully understood and compensated for. Currently, full
quantification of regional radiotracer activity is not yet
possible. This precludes the calculation of standardised
uptake values (SUVs) as an established semiquantitative
measure of radiotracer accumulation and local uptake needs
to be scaled towards a reference tissue. This current deficit
is expected to be amended soon by implementing a
calibration workflow.
One disadvantage of this prototype system mainly
designed for brain imaging is the small axial field of view
of the PET component of approximately 19.1 cm. The
typical field of view can be seen in the fused PET/MRI
images of Fig. 1. Therefore, hybrid PET/MRI with the
current system is limited to head and neck tumours located
cranially of the angle of the mandible. Tumours of the
hypopharynx or the larynx currently cannot be assessed
with the existing prototype systems. Also, a complete staging
of the cervical lymph nodes is not feasible. However, in many
cases the optimally correlated PETand MRI datasets obtained
with the existing hybrid device may significantly improve
assessment of the primary tumour, especially in the skull base
and upper pharynx region. Additional whole-body CT or
PET/CT may complement PET/MRI for staging purposes.
The response to treatment of reference lesions within the PET/
MRI’s field of view may be another important application of
this imaging device.
There are two limitations of the current study design:
First, according to the approval of the local Ethics
committee, the application of contrast medium was not
allowed. Therefore, post-contrast MR imaging of the
tumour extension could not be compared with the PET
datasets. Second, the remaining FDG tracer from the
clinically indicated PET/CT was used for PET/MRI.
Therefore, the uptake time for FDG was not identical in
both measurements. However, metabolic trapping of FDG
was relatively stable over the duration of PET/CT and PET/
Fig. 5 Correlation of PET/MRI and PET/CT metabolic ratios for head
and neck tumours (mean and maximum values). The line of identity is
drawn as a dotted line. The correlation coefficients were 0.92 for the
mean values (regression line (solid): y=0.89×+0.02) and 0.96 for the
maximum values (regression line (dashed): y=0.80×+0.06)
Fig. 4 Correlation of averaged metabolic ratios of physiological
tracer uptake in regular physiological structures. The line of identity is
displayed as a dotted line. The correlation coefficient was R=0.99
with the linear regression line (solid line): y=0.85×+0.04
PET/MRI PET/CT Sample size Literature values
Base of tongue, lingual tonsil 0.433±0.116 0.411±0.179 7 0.40
Gingiva 0.362±0.186 0.347±0.136 8 0.30–0.35
Nasopharynx, adenoids 0.416±0.151 0.322±0.100 8 0.40–0.49
Palatine tonsil 0.737±0.350 0.626±0.301 5 0.55–0.72
Parotid gland 0.239±0.079 0.268±0.08 8 0.30–0.32
Sublingual gland 0.547±0.187 0.544±0.226 6 0.39–0.56
Turbinates 0.233±0.128 0.241±0.089 7 0.34
Table 2 Mean metabolic ratios
of different physiological soft
tissue structures of the head
and neck calculated from
PET/MRI datasets in compari-
son to PET/CT and literature
values [10, 11]
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MRI; thus, the datasets are still comparable. The count loss
due to radioactive decay between the PET/CT and PET/MRI
measurements is more than compensated for by the longer
PET acquisition time with the PET/MRI system and an
improved sensitivity of the BrainPET compared to the PET
component of the PET/CT system.
The present data show that there is a considerable
overlap of uptake ratios between tumour and regular
anatomical structures even for the PET insert with the
better resolution and subsequent lesser spill-over and partial
volume effects. The complementary and optimally spatially
correlated MRI data may enhance tumour assessment. The
advantages, other than improved workflow and patient
comfort, of the hybrid PET/MRI technology over PET/CT
or retrospectively correlated PET and MRI data remain to
be discovered in future clinical studies.
Due to the small craniocaudal field-of-view of only
19.1 cm, the hybrid PET/MRI system applied in this study
(Siemens BrainPET) cannot replace PET/CT imaging in
most of its indications, e.g. evaluation of regional nodal
involvement caudal of the cervical level II, detection of
second primary tumours, detection of distant metastases in
patients with advanced head and neck malignancies, and
evaluation of patients with unknown primaries. Due to its
high spatial resolution, the system could potentially be
applied with promising results in monitoring of therapy
response and in treatment planning especially of new
treatment’s modalities such as intensity-modulated radiation
therapy or image guided stereotactic radio surgery. The
upcoming new generation of hybrid whole-body PET/MRI
scanners probably could often replace conventional PET/
CT imaging, which has to be shown in future studies.
In conclusion, we showed that simultaneous PET/MRI
of the head and upper neck region is feasible with the
available prototype PET/MRI system. Thus, hybrid PET/MRI
can be used to obtain the often complementary information
from MR and PET imaging very efficiently and with optimal
spatial and temporal coregistration. The MR-compatible
prototype PET system used (Siemens BrainPET) offers a
higher spatial resolution compared with conventional PET/CT
systems, which seems advantageous in cases of head and
upper neck malignancies.
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